Premium
Platelet α 2 ‐ and leucocyte β 2 ‐adrenoceptors in phaeochromocytoma: effect of tumour removal
Author(s) -
VALET P.,
DAMASEMICHEL C.,
CHAMONTIN B.,
DURAND D.,
CHOLLET F.,
MONTASTRUC J. L.
Publication year - 1988
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1988.tb01043.x
Subject(s) - platelet , yohimbine , medicine , endocrinology , catecholamine , in vivo , adrenergic receptor , pheochromocytoma , chemistry , pharmacology , receptor , biology , antagonist , microbiology and biotechnology
Platelet α 2 ‐ and leucocyte β 2 ‐adrenoceptors (as well as noradrenaline and adrenaline plasma levels) were studied in five patients with confirmed phaeochromocytoma using tritiated yohimbine and iodated cyanopindolol, respectively, before and after tumour removal. Patients with phaeochromocytoma had a lower leucocyte iodated cyanopindolol binding than control subjects, but no change in platelet tritiated yohimbine binding. Plasma catecholamine levels were higher than controls. Tumour removal induced a return to normal values of leucocyte iodated cyanopindolol binding and a decrease in plasma catecholamine levels. These results underline the potential interest of leucocyte β ‐adrenoceptor quantification in the diagnosis and the follow‐up of phaeochromocytoma. Pharmacologically, they show that down‐regulation occurs in vivo for leucocyte β 2 ‐adrenoceptors but not for platelet α 2 ‐adrenoceptors.